Updated:
Ikarian Capital
Ikarian Capital is an SEC-registered investment adviser in Dallas, TX, registered since 2020. The firm manages approximately $698 million in regulatory assets.
Ikarian Capital
Ikarian Capital is an SEC-registered investment adviser in Dallas, TX, registered since 2020. The firm manages approximately $698 million in regulatory assets. It has 8 employees and 3 investment advisers.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Dallas
Corporate office
100 Crescent Court, Suite 1620, Dallas, TX 75201, United States
Additional offices
San Diego · San Francisco
Sector focus
Frequently asked questions
Who leads investment decisions at Ikarian Capital?
The founding team is composed of professionals with scientific and finance backgrounds, but individual principals are not named publicly on the firm's website. The team’s combined expertise spans drug discovery and biotech-specific finance.
How does Ikarian Capital source proprietary deal flow?
The firm claims a proprietary process that relies on its team's core expertise in biotech science and finance. It describes itself as selective and contrarian, seeking opportunities overlooked by larger investors. Specific sourcing methods or networks have not been detailed publicly.
What investment stages does Ikarian Capital target?
Ikarian Capital invests across the entire clinical development spectrum, from early- to late-stage trials. It is agnostic to indication, market cap, and geography, allowing flexibility in stage preference based on scientific merit.
Which sectors does Ikarian Capital explicitly avoid?
The firm is solely focused on biotech and therapeutic innovation. It does not invest in sectors outside drug discovery and development, such as real estate, energy, or consumer goods.
Is Ikarian Capital structured as a single family office or an investment firm?
Ikarian Capital presents itself as a biotech investment firm, not as a family office. Its website and registered address indicate an institutional structure, but its ownership and capital sources are not publicly disclosed.
Does Ikarian Capital participate in fund commitments or only direct deals?
The firm's website emphasizes direct investments in emerging biotech companies. It refers to deploying 'transformation capital' to support companies through the clinic, suggesting a focus on direct equity positions rather than fund-of-funds or secondary commitments.
Where does the underlying wealth come from?
The origin of Ikarian Capital's capital is not publicly disclosed. The firm does not attribute its funding to any specific individual, family, or institution.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on registered investment advisers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: